

WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L68100DL1996PLC227773

Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, Delhi, India, 110092

Email: welcuredrugs227@gmail.com Website: <https://welcure.co.in/>

Date: 01st December, 2025

To,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Reference: ISIN- INE331C01017; Scrip Code- 524661; Symbol- WELCURE

Sub: Intimation of Rights Issue Committee Meeting to be held on 05th December, 2025 for deciding Issue Price and other terms of the Rights Issue.

Dear Sir/Madam,

This is further to our Outcome of the meeting of the Board of Directors (“**Board**”) of Welcure Drugs and Pharmaceuticals Limited (“**Company**”) dated Monday, December 01, 2025 wherein the offer and issuance of fully paid-up equity shares of face value of Rs. 1.00/- each of the Company (“**Rights Equity Shares**”) as decided by the Board by way of a Rights Issue, to the eligible Shareholders, for an amount not exceeding Rs. 49,00,00,000/- (Rupees Forty Nine Crores Only) (“**Rights Issue**”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, SEBI Listing Regulations and other applicable laws, was approved.

Further to the above and in compliance with Regulation 29(1)(d) of the SEBI Listing Regulations, we hereby inform you that a meeting of the Rights Issue Committee is scheduled to be held on Friday, December 05, 2025, inter alia, to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the Rights Issue price and related payment mechanism, rights entitlement ratio, the record date, timing of the Rights Issue and other terms and conditions with respect to the Rights Issue.,

Further this is to inform you that as per the SEBI (Prohibition of Insider Trading) Regulation, 2015 as amended from time to time and the Company’s Code of Conduct to regulate, monitor and report the trading of equity shares, the Trading Window for dealing in the securities of the company by the designated persons and their immediate relatives of the company has been closed from today i.e. December 01, 2025 and shall remain closed till 48 hours from the closure of the Right Issue Committee Meeting.

This intimation is also being made available on the Company’s website at <https://welcure.co.in/>

You are requested to please take the same in your record.

For Welcure Drugs & Pharmaceuticals Ltd.

**Chintan Didawala Ganpat
Managing Director
Din: 11088268**